The FDA has announced mandatory labeling changes for all opioid pain medications to more clearly communicate the risks associated with long-term use, including addiction, overdose, and other serious harms....
The FDA announced on June 12 that it has approved pembrolizumab for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1.
This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in April and May, including treatment for menopausal hot flashes, Clostridioides difficile infection, suspected opioid...
This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in April and May, including treatment for menopausal hot flashes, Clostridioides difficile infection, suspected opioid...
The FDA has approved an implantable neurostimulation system designed for the treatment of intractable chronic low back pain associated with multifidus muscle dysfunction.
After results from a clinical trial demonstrated its safety and efficacy, the US Food and Drug Administration recently approved the first and only extended-release intra-articular injection for patients...
